Methods and compositions for modulating and detecting wisp activity
AssigneeGenentech, Inc.
InventorsLuc Desnoyers, Ellen Filvaroff
Life of this patent
Estimating the term…
Abstract
Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell. The invention also provides methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with native WISP-1 polypeptides.
Claims28
An isolated WISP-1-domain 1 polypeptide consisting of amino acids 24-117 of SEQ ID NO:1.
An isolated WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide is at least about 95% identical to amino acids 24-117 of SEQ ID NO:1 and wherein said WISP-1-domain 1 polypeptide inhibits the motility of pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells, and/or brain cancer cells.
A composition comprising a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of amino acids 24-117 of SEQ ID NO:1.
A composition comprising a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide is at least about 95% identical to amino acids 24-117 of SEQ ID NO:1 and wherein said WISP-1-domain 1 polypeptide inhibits the motility of pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells, and/or brain cancer cells.
A method of treating pancreatic cancer, colon or colorectal cancer, breast cancer, lung cancer, or brain cancer in a mammal, comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide consisting essentially of amino acids 24-117 of SEQ ID NO:1.
A method of inhibiting cancer cell motility, comprising exposing a pancreatic cancer cell, colon or colorectal cancer cell, breast cancer cell, lung cancer cell, or brain cancer cell to an effective amount of a WISP-1-domain 1 polypeptide consisting essentially of amino acids 24-117 of SEQ ID NO:1.
A method of inhibiting cancer cell motility in a mammal comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide consisting essentially of amino acids 24-117 of SEQ ID NO:1,
- wherein said cancer cell is selected from the group consisting of a pancreatic cancer cell, colon or colorectal cancer cell, breast cancer cell, lung cancer cell, or brain cancer cell.
A method of treating pancreatic cancer, colon or colorectal cancer, breast cancer, lung cancer, or brain cancer in a mammal, comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide is at least about 95% identical to amino acids 24-117 of SEQ ID NO:1 and wherein said WISP-1-domain 1 polypeptide inhibits the motility of pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells, and/or brain cancer cells.
A method of inhibiting cancer cell motility, comprising exposing a pancreatic cancer cell, colon or colorectal cancer cell, breast cancer cell, lung cancer cell, or brain cancer cell to an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide is at least about 95% identical to amino acids 24-117 of SEQ ID NO:1 and wherein said WISP-1-domain 1 polypeptide inhibits the motility of pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells, and/or brain cancer cells.
A method of inhibiting cancer cell motility in a mammal comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide is at least about 95% identical to amino acids 24-117 of SEQ ID NO:1 and wherein said WISP-1-domain 1 polypeptide inhibits the motility of said cancer cell, and further wherein said cancer cell is selected from the group consisting of a pancreatic cancer cell, colon or colorectal cancer cell, breast cancer cell, lung cancer cell, or brain cancer cell.
Dependencies are inferred from the claim text.